Despite major advances in the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF), morbidity and mortality associated with the condition remain high, suggesting the need for additional treatment options, particularly haemodynamically neutral treatments that do not alter blood pressure, heart rate, or renal function. HF with preserved ejection fraction (HFpEF) is also associated with high morbidity and mortality and adequate treatment options are limited; thus there is a critical unmet need for the development of novel therapies for HFpEF. Chronic HFrEF and HFpEF are both systemic disorders that affect not only the heart but several other tissues and organs including skeletal muscle, leading to exercise intolerance and dyspnoea. Partial adenosine A1-receptor agonists represent a novel potential therapy for HF regardless of underlying ejection fraction given their minimal effect on heart rate and blood pressure, and preclinical data demonstrate several possible beneficial mechanisms, including improved mitochondrial function and sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) activity, enhanced energy substrate utilization, reverse ventricular remodelling, and anti-ischemic, cardioprotective properties. However, data on this class of drugs in humans are scarce, and the optimal dose of the partial adenosine A1 receptor, neladenoson bialanate, has not been defined. Here we describe the design and rationale of two randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase 2b trials, PANTHEON (HFrEF) and PANACHE (HFpEF), that will advance our understanding of the potential benefit and optimal dose of neladenoson bialanate and provide critical information for the planning of future phase 3 trials.
Introduction
Over the past few decades, several drugs and devices have considerably improved clinical outcomes in patients with heart failure (HF) and a reduced ejection fraction (HFrEF).
1 -3 The majority of these therapies are centered around systemic blockade of maladaptive neurohormonal responses, such as the enhanced and sustained activities of the sympathetic and renin-angiotensin-aldosterone systems. However, mortality and morbidity in patients with HFrEF remains high, in particular in those who have been hospitalized for worsening signs and/or symptoms of HF. In addition, although highly effective, the use of these treatments can be limited by renal dysfunction, electrolyte disturbances, hypotension, and bradycardia. Therefore, because of the high residual risk in HFrEF and limitations of current treatments, additional and/or alternative therapies for the treatment of patients with HFrEF are still required.
For patients with HF and a preserved ejection fraction (HFpEF), no pharmacological treatments have as yet convincingly been shown to reduce morbidity, mortality, and/or exercise intolerance.
1 -5 Several neurohormonal blockers, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, have been studied, but in contrast to the results seen in patients with HFrEF, trials in patients with HFpEF showed largely neutral results. These findings highlight our limited understanding of the pathophysiology of HFpEF and the need for new treatment targets. 5 
Mode of action
Despite clinical, pathophysiological, and treatment response differences between HFrEF and HFpEF, they appear to share pathophysiological mechanisms. Two of these common mechanisms underlying myocardial dysfunction in HF are (i) impaired mitochondrial function, present from early in the development of HF, and (ii) an impaired contraction/relaxation coupling resulting from a decreased activity of the sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) and an associated reduction in calcium handling in cardiomyocytes. Both of these mechanisms can be targeted by the activation of adenosine A1 receptors. In contrast, previously, adenosine A1-receptor antagonists were studied for the treatment of patients with acute decompensated HF. The rationale behind these earlier studies was that adenosine A1-receptor antagonists improved renal function by stimulating renal vessel relaxation and inhibiting the so-called tubuloglomerular feedback mechanism, thereby improving renal perfusion and hence increasing natriuresis and diuresis. It was hypothesized that this led to an improvement in the clinical outcome of acute decompensated HF. Despite promising results from phase 2 and mechanistic studies, a large phase 3 trial of rolofylline, an adenosine A1-receptor antagonist, in 2033 patients with acute decompensated HF failed to demonstrate an effect on a combined clinical outcome endpoint. 6 Rolofylline treatment was associated with an increased rate of seizures and stroke compared with placebo, as well as a lack of effect . on renal impairment. One of the potential reasons for the neutral clinical results of this trial is that the inhibition of adenosine A1 receptors might have negative effects on the kidney, owing to the missing renoprotective effect of adenosine A1-receptor activation previously demonstrated in preclinical studies. Additionally, a partial A1-receptor agonist can act as a weak antagonist at high endogenous adenosine levels. Therefore, a mixture of agonistic and antagonistic effects on renal tissue might comprise the optimal mechanism for renal protection in patients with HF. These findings, and the potential cardiac beneficial effects of adenosine, led to the development of adenosine A1-receptor agonists.
Neladenoson bialanate (BAY 1067197, which is the free base of the hydrochloride BAY 86-8901) is the prodrug of the pharmacologically active compound neladenoson (BAY 84-3174), a highly potent and selective non-adenosine-like partial adenosine A1-receptor agonist suitable for once daily oral use. 7, 8 The reason for the development of a partial adenosine A1-receptor agonist is that the use of full A1-receptor agonists in HF has been limited by undesirable cardiac effects such as negative inotropic, chronotropic, and dromotropic effects, including high-degree atrioventricular (AV) block, in particular with the concomitant use of -blockers. 8 In addition, a full agonist might have undesired extracardiac effects such as anti-diuretic effects (caused by vasoconstriction of the renal afferent arterioles) and neurological effects such as sedation. A partial adenosine A1-receptor agonist might overcome these undesired side effects while preserving the potentially beneficial cardioprotective effects of adenosine, depending on the tissue-specific receptor reserve for determined pharmacological effects and on the effects of endogenous adenosine.
7
Figure 1 summarizes the possible beneficial effects of partial adenosine A1-receptor agonists, which can be summarized in five domains: (i) improving impaired mitochondrial function, (ii) enhancing SERCA2a activity, (iii) increasing myocardial energy substrate utilization, (iv) preventing ventricular remodelling, and (v) providing anti-ischemic cardioprotection. Of note, partial adenosine A1-receptor agonists can improve mitochondrial function in skeletal muscle as well as in the heart, a potentially important effect because skeletal muscle dysfunction is a significant contributor to exercise intolerance in both individuals with HFrEF and those with HFpEF. Beneficial effects beyond the heart may be valuable because HFpEF in particular is now recognized as a systemic, multi-organ syndrome.
Partial adenosine A1-receptor agonists can also normalize the disturbed SERCA2a protein levels in HF models, and thereby potentially improve the activity of the SERCA2a calcium pump. 7 In patients with HF, the normal, orderly transport of calcium ions in and out of the sarcoplasmic reticulum is dysregulated for several reasons, including dysfunction of SERCA2a. 9 In preclinical studies of HF, treatment with the partial adenosine A1-receptor agonist capadenoson prevented the decline in SERCA2a activity that was observed in the untreated control group. Furthermore, treatment with capadenoson resulted in a normalization of SERCA2a affinity. In addition, in dogs with HFrEF, treatment with capadenoson was associated with a significant increase in SERCA2a protein Figure 1 Adenosine A1-receptor agonists: advantages of partial agonists compared with full agonists, and proposed mechanisms underlying potential beneficial effects on cardiac and skeletal muscle performance. Preclinical data (bottom left) show that the partial adenosine A1-receptor agonist only partially activates the A1 receptor, thereby avoiding the potential cardiac, neurological, and renal adverse effects of full agonists. Partial A1-receptor agonists have multiple potential benefits (right); these could improve both cardiac and skeletal muscle performance which are relevant to all patients with heart failure, regardless of underlying ejection fraction. AV, atrioventricular; SERCA2a, sarcoplasmic reticulum Ca 2+ -ATPase. expression compared with no treatment, achieving near-normal levels.
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In addition to improving mitochondrial function and enhancing SERCA2a activity, other reported beneficial effects of adenosine partial A1-receptor agonists include optimization of myocardial energy substrate utilization, prevention of ventricular remodelling (with a reduction in myocardial fibrosis and improved systolic and diastolic function), and anti-ischemic cardioprotective effects, which are in part due to improved cardiomyocyte calcium handling as well as decreased sensitivity to sympathetic over-stimulation. 7, 8, 11, 12 
Clinical trial data
The safety and tolerability of neladenoson bialanate has been studied in two small pilot studies in patients with HFrEF.
12 An initial -blocker interaction study-a single-blind, placebo-controlled study on the effects of a single 30 mg dose of neladenoson bialanate on AV conduction-was conducted in 11 patients with HFrEF treated with -blockers. In this study, neladenoson bialanate was well tolerated and no second-or third-degree AV block was detected on 48 h ambulatory electrocardiographic monitoring. The Partial Adenosine Receptor Agonist in Heart Failure (PARSiFAL) pilot study was a double-blind, placebo-controlled study of the effects of 7-day treatment with 10 mg or 20 12 In this small study, neladenoson bialanate was also well tolerated-no episodes of second-or third-degree AV block or detrimental effects on heart rate or blood pressure were observed. In addition, no clinically relevant neurological side effects were seen. Median absolute changes in ejection fraction, measured by cardiac magnetic resonance, were + 1.9% (interquartile range -1.1 to 4.3%), 0.3% (-1.4 to 2.7%), and 2.2% (0.4 to 4.5%), in the placebo, 10 mg, and 20 mg groups, respectively; there was no statistically significant difference between groups.
12 To further study the safety, tolerability, and efficacy of neladenoson bialanate in patients with HFrEF and HFpEF, we designed two separate phase 2 studies, described in detail below.
Methods

Objectives
The objectives of PANTHEON and PANACHE are to inform future phase 3 trials by identifying the optimal dose of neladenoson bialanate, by examining dose-response relationships in terms of the efficacy endpoint(s) of the respective studies, and by characterizing the safety, tolerability, and pharmacodynamic effects of the compound when administered in addition to standard therapy. An exploratory objective is to further assess pharmacokinetic parameters and blood and urine biomarkers. 
Study design
PANTHEON is a multicentre, randomized, double-blind, placebocontrolled, parallel-group, dose-finding phase 2 trial of the effects of neladenoson bialanate in individuals with HFrEF. Approximately 460 participants from approximately 90 study centres worldwide will be entered into the run-in phase. After drop-outs in the run-in phase we aim to randomize 384 patients to a once-daily dose of neladenoson bialanate (5, 10, 20, 30, or 40 mg) or placebo, in addition to standard of care, guideline-directed HF therapy ( Figure 2) . The study will comprise a 1-week run-in period, a 20-week treatment period, and a 6-week follow-up period (27 weeks in total). The purpose of the 1-week run-in period is to allow for collection of data on activity (duration, intensity) and continuous 7-day cardiac rhythm monitoring with the AVIVO patch (Medtronic, Minneapolis, MN, USA) prior to study drug intake in order to secure an appropriate baseline assessment. In addition, for the PANACHE trial, the run-in visit was used to perform the 6-minute walk test (6MWT) to familiarize the patient with it and to minimize training effects during the trial. Safety will be monitored throughout the study. Samples will be taken for pharmacokinetic analyses from all patients at dedicated time points. Additional biomarkers reflecting the pharmacodynamic activity of the drug will be examined, as well as candidate biomarkers that may predict drug response. The anticipated total duration of the study is approximately 19 months, including an anticipated recruitment period of 13 months followed by a run-in period of 1 week, a treatment period of 20 weeks, and a follow-up period of 6 weeks after enrolment of the last patient.
PANACHE is a multicentre, randomized, double-blind, placebocontrolled, parallel-group, dose-finding phase 2 trial to study the efficacy, safety, pharmacokinetics, and pharmacodynamic effects of neladenoson bialanate over 20 weeks in individuals with chronic HFpEF. Approximately 350 patients from approximately 90 sites will be randomized to a once-daily dose of neladenoson bialanate (5, 10, 20, 30, or 40 mg) or placebo ( Figure 2) . The study will include the same schedule of study visits and calls as the PANTHEON study. Safety will be monitored throughout the study. Samples for pharmacokinetic analyses will be taken from all patients at specific time points. reflecting the pharmacodynamic activity of the drug will be examined, as well as candidate biomarkers that may predict drug response.
Patient enrolment criteria
The full descriptions of inclusion and exclusion criteria for PAN-THEON and PANACHE are provided in the supplementary material online, Table S1 and Table S2 , respectively. Key inclusion criteria for both studies are listed in Table 1 . PANTHEON includes patients (aged ≥18 years) with a diagnosis of chronic symptomatic HFrEF [New York Heart Association (NYHA) functional class II-IV; left ventricular ejection fraction (LVEF) ≤35%]. The diagnosis of HF must be confirmed by either: (i) an episode of worsening chronic HF requiring hospitalization or an unscheduled outpatient visit in the past 3 months, both requiring initiation or intensification of HF therapy; and (ii) elevated natriuretic peptides. Patients with acute new-onset HF are excluded and only participants with either ischaemic or idiopathic cardiomyopathy are allowed entry into the study.
PANACHE includes patients aged ≥45 years with a diagnosis of chronic HFpEF (NYHA class II-IV), without evidence of a non-cardiac explanation for dyspnoea. Enrolled patients must have a LVEF ≥45% within the previous 6 months with no significant change in clinical status suggesting the potential for deterioration in LVEF. Also, patients with a historical LVEF <40% are excluded. In the 6 months prior to run-in, participants should have been treated with a diuretic and should have a history of elevated natriuretic peptides documented in the medical record. Finally, patients should have documented left atrial enlargement, left ventricular hypertrophy, or invasively measured elevated left ventricular filling pressures. At baseline the 6-minute walk distance (6MWD) must be in the range 100-550 m. • BNP ≥100 pg/mL or NT-proBNP ≥400 pg/mL (sinus rhythm) or • BNP ≥300 pg/mL or NT-proBNP ≥1200 pg/mL (atrial fibrillation)
AND/OR
In the 6 months prior to run-in: a) Requirement for treatment with a diuretic AND b) Elevated natriuretic peptides, defined as one of:
• BNP ≥75 pg/mL or NT-proBNP ≥300 pg/mL (sinus rhythm) or • BNP ≥200 pg/mL or NT-proBNP ≥900 pg/mL (atrial fibrillation) AND at any time in the past 4 weeks, one of:
• BNP ≥300 pg/mL or NT-proBNP ≥1200 pg/mL (sinus rhythm) • BNP ≥600 pg/mL or NT-proBNP ≥2400 pg/mL (atrial fibrillation) • For patients on treatment with angiotensin receptor-neprilysin inhibitors, only NT-proBNP values can be used to assess eligibility at least one of the following:
• LA enlargement (LA diameter ≥ 3. (NT-proBNP), troponin, markers of renal function]; quality of life questionnaires [5-dimension EuroQol questionnaire (EQ-5D), Kansas City Cardiomyopathy Questionnaire, 13 -15 Borg Dyspnoea Scale]; 6MWT (6MWT combined with Borg Dyspnoea Scale; PANACHE only); and comprehensive echocardiography, including speckle-tracking strain analysis for global longitudinal strain (measured by an independent, blinded core laboratory). The 6MWT will be conducted at screening and again at the baseline randomization visit to take account of familiarization effects; 16 the baseline randomization visit 6MWD will be used for analysis of the 6MWD endpoint. Novel measures include continuous cardiac rhythm monitoring with the AVIVO patch, for collection of data on activity (duration, intensity) and continuously monitor cardiac rhythm for safety assessment. The AVIVO patch is applied to the participant's chest for seven consecutive days four times during the study.
Efficacy variables
The complete list of primary, secondary, exploratory, and safety variables of PANTHEON are described in Table 2 . The primary study outcomes are (i) the absolute change from baseline in LVEF (%) after 20 weeks of treatment, as measured by echocardiography, and (ii) the absolute change from baseline in log-transformed NT-proBNP after 20 weeks.
. The complete list of primary, secondary, exploratory, and safety variables of PANACHE are described in Table 3 . The primary study endpoint is the absolute change from baseline in 6MWD after 20 weeks of treatment. Secondary outcomes are changes from baseline to 20 weeks of treatment in: (i) activity (e.g. duration, intensity); (ii) NT-proBNP; (ii) high-sensitivity troponin T; and (iv) quality of life.
Trial organization
The countries participating in each trial are shown in Figure 3 . All study sites irrespective of trial have approval from their local ethics committee or institutional review board, as well as applicable country and local regulatory approval. These studies are being conducted under the International Conference on Harmonisation Good Clinical Practice consolidated guideline. All patients enrolled in PANTHEON and PANACHE will provide written informed consent, and the studies will be led by separate steering committees composed of experts in HFrEF and HFpEF, respectively. Throughout the trial an independent data monitoring committee (DMC) composed of cardiologists, an electrophysiologist, and a biostatistician will review unblinded safety data for both trials. The compositions of the two steering committees and the DMC can be found in the supplementary material online, Appendix S1. -Change in renal function measured by eGFR change from baseline -Change in liver function measured by bilirubin (total and fractions), AST, and ALT from baseline 3. 12-lead ECG abnormalities and PR interval duration 4. Blood pressure and heart rate; measured values and change from baseline 5. Number of clinically significant findings on ECG and/or AVIVO device report AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AV, atrioventricular; CV, cardiovascular; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; EQ-5D-5 L, 5-level 5-dimension EuroQol questionnaire; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; SAE, serious adverse event; UACR, urine albumin to creatinine ratio.
Statistical considerations
To evaluate the primary and secondary outcomes in both studies, we shall combine multiple comparison procedure (MCP) principles with modelling techniques under model uncertainty (the MCP-Mod approach), comprising two key steps.
Step 1 is the inferential step: this is a one-sided multiple contrast test for an efficacy signal (a non-flat dose-response curve) while controlling for type 1 error ( = 5%). A set of five candidate shapes (a linear model, an E max model, sigmoidal E max models 1 and 2, and a quadratic model) was predefined to cover both plausible and diverse dose-response profiles, reflecting the range of candidate models believed to be capable of describing the dose-response relationship at the study design stage.
Step 2 is the estimation step: if a dose-response signal is established in step 1, a dose-response model and target dose(s) of interest will be estimated.
For both PANTHEON and PANACHE, a dose-response signal is shown in the primary efficacy analysis if at least one of the two null hypotheses related to the primary efficacy variables can be rejected. The Hochberg (step-up) procedure will be applied to control the family-wise error rate. Based on the assumption of a maximum effect for absolute increase in LVEF of 5% for a dose of neladenoson bialanate, an absolute increase of ≤2% under placebo, and a standard deviation of 7%, an overall sample size of 288 randomly allocated patients (using a 1:2:2:2:2:3 allocation ratio corresponding to the neladenoson bialanate 5, 10, 20, 30, and 40 mg dose groups and placebo) is required to ensure a minimum power of 80% to detect the presence of a dose response in the PANTHEON study.
Based on the assumption of a maximum effect for absolute increase in 6MWD of 40 m for a dose of neladenoson bialanate, an absolute increase of 0 m under placebo, and a standard deviation of 80 m, an overall sample size of 216 randomly allocated patients (using a 1:2:2:2:2:3 allocation ratio corresponding to the neladenoson bialanate 5, 10, 20, 30, and 40 mg dose groups and placebo) is required to ensure a minimum power of 80% to detect the presence of a dose response in the PANACHE study.
These power calculations were based on simulations that use all five candidate models considered for dose-response modelling. Taking into account both primary outcomes in PANTHEON, simulations showed that the power to reject at least one of the two primary null hypotheses would fall to <80% only if the relative reduction in NT-proBNP from baseline within the neladenoson bialanate investigated dose range is <27.5%, compared with an expected reduction from baseline of 10% under placebo. To allow for a drop-out rate of up to 25% in both studies, we aim to enrol 384 patients (96 in the placebo group, 32 in the 5 mg dose group, and 64 in each of the other active treatment groups) in PANTHEON and 288 patients (72 in the placebo group, 24 in the 5 mg dose group, and 48 in each of the other active treatment groups) in PANACHE.
Discussion
Justification of inclusion and exclusion criteria
PANTHEON will enrol patients with an established diagnosis of HFrEF, either of ischaemic origin or due to idiopathic dilated cardiomyopathy. The natriuretic peptide criteria in combination with a previous hospitalization for HF will help ensure the inclusion of patients with a well-established diagnosis of HF. A low LVEF cut-off value of ≤35% was chosen given that improvement in LVEF is one of the primary efficacy variables of this study. shown to have a significant effect on blood pressure, although there are relatively limited data available. However, for safety reasons, patients with a systolic blood pressure ≤ 90 mmHg will be excluded. The aim of the PANACHE inclusion and exclusion criteria is to ensure that enrolled patients have HFpEF. Criteria that are too lenient could lead to the inclusion of participants who may not have HFpEF, whereas criteria that are too strict would hamper recruitment rates and might lead to the selection of patients with relatively advanced HF who may be less responsive to treatment. The entry level of natriuretic peptides was lower for PANACHE than for PANTHEON. The reason behind this was that natriuretic peptides are generally lower and have a particularly high day-to-day variability in HFpEF, and a requirement for elevated natriuretic peptide makes trial recruitment challenging, in particular for HFpEF trials. Furthermore, by using higher thresholds, sicker or less well treated patients may be included. In addition, PANACHE allows for the use of historical (prior 6 months) natriuretic peptide levels to help ease enrolment at sites (because PANACHE does not have decrease in natriuretic peptide as the primary efficacy variable, an elevated level on the day of enrolment is not required for inclusion into the study). Interestingly, in retrospective analyses of both the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist [TOPCAT (spironolactone)] trial 18 and Figure 3 Participating countries and numbers of sites per country for PANTHEON and PANACHE.
the Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve (irbesartan)] trial, 19 patients with lower natriuretic peptide levels appeared to benefit most from study treatment, although findings from post hoc analyses must be observed with caution. Finally, the LVEF cut-off value of ≥45% was a compromise in response to diverging opinions as to the LVEF threshold that should be used to define HFpEF.
1 -3 Although the LVEF cut-off values of ≤35% in PANTHEON and ≥ 45% in PANACHE are non-overlapping, prior studies have shown that values from echocardiography core laboratories differ from investigator-reported values, and it is expected that the whole range of LVEF values will be included in the trials.
Justification of the efficacy variables
PANTHEON and PANACHE are phase 2 trials designed to find the optimal dose of neladenoson bialanate for a potential phase 3 trial. Ideally, the efficacy variables used should reflect the mode of action of the drug, have clinical meaning by themselves, and reflect a likely improvement in 'hard' clinical outcomes in a potential phase 3 trial. Given the possible mechanism of action of neladenoson bialanate in improving mitochondrial function and SERCA2a activity, LVEF was chosen as the primary endpoint in PANTHEON, assuming an increase would be (i) potentially related to the mode of action of the drug, translate to an improvement in the clinical outcomes commonly used in phase 3 HFrEF trials. NT-proBNP was chosen as an additional primary endpoint because changes in NT-proBNP are also a reasonable surrogate for predicting success in phase 3 trials. Six-minute walk distance was chosen as the primary efficacy variable in PANACHE for two main reasons. First, patients with HFpEF have exercise intolerance, manifested as exertional dyspnoea and fatigue, which is associated with reduced quality of life and correlates with subsequent clinical events; this intolerance can be assessed objectively by standardized exercise tests including the 6MWT. Further, improvement in exercise capacity in patients with HFpEF is in itself a potentially approvable phase 3 endpoint, provided any such improvement is not counteracted by adverse clinical effects. Secondly, given the potential effects of neladenoson bialanate on mitochondrial function in both cardiac and skeletal myocytes, an improvement in 6MWD may directly reflect the mode of action of this therapy. 20 However, in both PANTHEON and PANACHE, no single surrogate endpoint will be sufficient to make a decision to move forward to a phase 3 trial. In making this decision the totality of data collected will be considered, including the different domains of (i) echocardiographic parameters, (ii) biomarkers, (iii) activity, and (iv) quality of life. The choice of the primary efficacy variable of 6MWD in PANACHE was used to power the trial accordingly, with the definition of success or failure of the study drug determined by the domain-based approach. PANACHE is the first phase 2 HFpEF trial designed in this way and will potentially help improve understanding of the utility of a domain-based approach in the future. This approach may be especially important in HFpEF, which is now viewed as a systemic, multi-organ syndrome, making the evaluation of a single parameter insufficient to predict clinical outcomes.
Justification of the dose finding
In line with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance ICH E4, and the importance of the elucidation of the dose-response function, the trials were planned as dose-ranging studies, with five active doses over the range 5-40 mg. While 5 mg is regarded as the minimum effective or sub-effective dose, 40 mg is considered a dose at which the full pharmacological effects should already be reached and no clinically meaningful further increase of cardiac function is expected. Consistent evidence of A1-receptor target engagement could be achieved in different tissues across prior clinical trials with 20 mg neladenoson bialanate; thus, the selected doses (5, 10, 20, 30, and 40 mg) were chosen to ensure a well-informed dose finding given the model uncertainty reflected by the set of pre-specified candidate models using the MCP-Mod approach. The doses studied will ensure a robust dose recommendation moving forward to phase 3.
Conclusions
Preclinical data demonstrating improved mitochondrial function, SERCA2a activity, energy substrate utilization, prevention of ventricular remodelling, and anti-ischemic cardioprotective properties suggest that partial adenosine A1-receptor agonists such as neladenoson bialanate might be of therapeutic value in HF, regardless of LVEF. The apparently minimal effect of neladenoson bialanate on heart rate, blood pressure, and renal function is also appealing. However, there are as yet limited data on the effects of partial adenosine A1-receptor agonists in humans, and the optimal dose of neladenoson bialanate, the leading candidate in this class of drugs, has not yet been defined. Thus the phase 2b PAN-THEON and PANACHE trials will be important in improving our understanding of the potential benefit of neladenoson bialanate in humans, and will provide important insights into whether phase 3 trials in HFrEF and HFpEF are warranted.
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